Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert

Forum Eli Lilly & Co US5324571083

Watchlist Alert Portefeuille
Koers ($) |
1.008,390  
Range | 980,58 - 1.008,93
+18,060   (+1,82%)
Volume
2.802.169
Bied
1.002,700
Laat
1.003,050
ELI

Eli Lilly and Company (LLY)

Volgen
Eerste post
46 Posts
vorige pagina 1 2 3 volgende pagina
Laatste
Omlaag
    Reactie Reactie van: dd20241014
    2. Reactie Reactie van: dd20241016
  2. forum rang 6 Lieutenant Price
    quote:

    nb schreef op 14 oktober 2024 19:48:

    Yep, ben er vorige week toch weer ingestapt. Novo durf ik ( nog) niet.
    Denk dat viking ook best goede kansen maakt met een pil.
    Welkom terug aan boord! :-)

    Novo Nordisk had ik onlangs op 785 DK gekocht, denk dat het op den duur wel weer zal herstellen richting 900 regionen.
    3. Reactie Reactie van: dd20241022
  3. forum rang 6 Lieutenant Price
    Lilly sues online vendors, medical spa over copycat weight-loss drugs

    "(Reuters) - Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets.

    The new lawsuits, which name Pivotal Peptides, MangoRx and Genesis Lifestyle Medicine of Nevada, are the first related to copycat tirzepatide filed since the U.S. Food and Drug Administration took the drug off its list of medicines in short supply earlier this month.

    Lilly said these lawsuits were not in any way contingent on tirzepatide coming off of that list and could have been filed regardless of whether supply issues had been resolved.

    Pivotal Peptides says it offers research grade tirzepatide, while MangoRx sells a compounded version, both online. Medical spa Genesis sells and administers compounded versions of the drug, according to the lawsuits.

    Lilly has accused Pivotal Peptides of selling products claiming to contain tirzepatide directly to patients without any prescription from a medical professional, despite advertising the drugs for research purposes.

    The lawsuits were filed in federal and state courts in Indiana, Texas and Washington, accusing each defendant of false advertising and promotion. Lilly said it sent a cease and desist letter to Pivotal Peptides before filing the lawsuit.

    "Lilly is bringing these actions to protect American consumers from direct patient safety risks," said a spokesperson for the drugmaker, adding that the defendants were making false claims about efficacy or safety, and misleading consumers about the clinical data used to back them.

    The Indianapolis-based drugmaker has already sued more than two dozen medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, which is also approved to treat type 2 diabetes under the brand name Mounjaro.

    In its most recent filings, Lilly said MangoRx was selling an oral version of tirzepatide branded as Trim, despite the lack of any study showing that formulation to be safe and effective. The FDA to date has only approved tirzepatide as an injectable drug.

    After Lilly sent Pivotal Peptides a cease and desist letter, the vendor changed its website to say it was under maintenance and altered its operations to sell via email, social media, and word of mouth, according to the drugmaker's lawsuit.

    Lilly said Genesis was claiming to sell compounded tirzepatide with vitamin B12, and that such combinations are "untested, unproven, and expose consumers to an unjustifiable risk of harm."

    Eli Lilly is seeking court orders barring the vendors from selling their drugs claiming to contain tirzepatide and unspecified monetary damages."
    finance.yahoo.com/news/lilly-sues-onl...
    4. Reactie Reactie van: dd20241028
    5. Reactie Reactie van: dd20241030
    6. Reactie
    7. Reactie Reactie van: dd20241106
    8. Reactie Reactie van: dd20241107
    9. Reactie Reactie van: dd20241126
  9. forum rang 6 Lieutenant Price
    Biden to propose expanded Medicare, Medicaid coverage of obesity drugs, official says


    "WASHINGTON (Reuters) -U.S. President Joe Biden on Tuesday proposed expanding coverage of anti-obesity drugs for millions on Medicare and Medicaid, which could cut out-of-pocket expenses for some by as much as 95%.

    This would enable more Americans to afford new weight loss medications that can help prevent type 2 diabetes and lower the risk of death and heart attacks by up to 20%, but cost as much as $1,000 a month without insurance coverage.

    Current rules for the Medicare and Medicaid government health insurance programs cover the use of drugs such as Mounjaro, Ozempic and Wegovy for certain conditions like diabetes, but not for obesity as a condition on its own.

    A new proposed regulation, to be published by the Department of Health and Human Services on Tuesday, would require Medicare to cover these drugs as a treatment for obesity, expanding access for an estimated 3.4 million Americans with Medicare.

    "Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees," the White House said in a statement.

    It would also ensure access to the medications for approximately 4 million adult Medicaid enrollees, it said."

    app.piqsuite.com/reuters/biden-to-pro...

    Eli Lilly and Company (LLY) 787.00 +32.00 (+4.24%) Pre-Market: 8:55 AM EST
    10. Reactie
    11. Reactie Reactie van: dd20241209
    12. Reactie Reactie van: dd20241213
    13. Reactie Reactie van: dd20241220
  13. forum rang 6 Lieutenant Price
    Eli Lilly and Company (LLY) 835.00 +77.46 (+10.23%) Pre-Market: 6:19:44 AM EST

    Novo Nordisk A/S (NOVO-B.CO) 571.20 -172.00 (-23.14%)

    Novo Nordisk shares tumble as weight-loss drug trial data disappoints

    "Novo Nordisk, one of Europe’s largest companies, lost more than a quarter of its value on Friday after its latest obesity drug missed the drugmaker’s goal for an average of 25 per cent weight loss.

    CagriSema helped patients lose an average of 22.7 per cent of their body weight in a late-stage trial, Novo Nordisk said on Friday, only marginally beating the results of rival Eli Lilly’s Mounjaro.

    Martin Holst Lange, executive vice-president for development at Novo Nordisk, said that only 57 per cent of patients had received the highest dose of the drug. “We are encouraged by the weight-loss profile of CagriSema,” he said.

    The company’s shares were down as much as 27 per cent in mid-morning trading in Denmark.

    Novo Nordisk and Eli Lilly are competing for dominance in a market that grew sevenfold in just three years to $24bn in 2023, according to data analytics firm Iqvia.

    Novo Nordisk had hoped its “next generation” weight-loss drug could lead the field, after its shares had struggled to keep pace with Eli Lilly and it suffered a setback from disappointing results for an experimental weight-loss pill in September.

    “CagriSema is really important for us,” chief executive Lars Fruergaard Jørgensen told the Financial Times in November. “It’s a next-generation product and it has the potential to be best in class.”

    Patients receiving Mounjaro lost an average of 22.5 per cent of their weight in phase 3 trials when taken as part of a regime of improved diet and exercise. Those on Wegovy, also made by Novo Nordisk, lost an average of about 15 per cent in similar conditions.

    About 40 per cent of patients in the CagriSema trial achieved 25 per cent weight loss over the 68 weeks.

    CagriSema combines semaglutide, the active ingredient in Wegovy and Ozempic, with cagrilintide, another hormone that makes people feel fuller for longer.

    The trial of 3,417 people taking the weekly injection found that the most common side effects were gastrointestinal, the vast majority of which were mild and moderate and diminished over time."

    www.ft.com/content/a91c249f-61f4-4613...
    14. Reactie Reactie van: dd20250113
  14. forum rang 10 voda
    Eli Lilly neemt borstkankerprogramma Scorpion over
    13-jan-2025 15:42

    Voor maximaal 2,5 miljard dollar.

    (ABM FN-Dow Jones) Eli Lilly neemt het borstkankerbehandelingsprogramma van Scorpion Therapeutics over. Dit meldden de Amerikaanse farmaceuten maandagmiddag.

    De aandeelhouders van het niet-beursgenoteerde Scorpion ontvangen tot 2,5 miljard dollar in de vorm van een vooruitbetaling en daaropvolgende betalingen afhankelijk van het behalen van regelgevende en verkoopmijlpalen.

    Als onderdeel van de overeenkomst zal Scorpion een nieuwe entiteit oprichten voor haar werknemers en pijplijnactiva die niet gerelateerd zijn aan het borstkankerbehandelingsprogramma.

    Dat nieuwe bedrijf komt in handen van de huidige aandeelhouders van Scorpion, terwijl Eli Lilly een minderheidsbelang krijgt.

    Wanneer de deal wordt afgerond is niet duidelijk.

    Aandelen van Eli Lilly noteerden maandag kort na de openingsbel op Wall Street 1,2 procent lager.

    Door: ABM Financial News.
    15. Reactie Reactie van: dd20250114
  15. forum rang 6 Lieutenant Price
    Lilly forecasts weak sales of weight-loss drug in fourth quarter

    "(Reuters) - Eli Lilly expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecast 2025 revenue largely above estimates.

    The company said on Tuesday it expects $3.5 billion in Mounjaro sales in the fourth quarter, and $1.9 billion for Zepbound. Analysts had expected the drugs to bring in $5.35 billion and $2.08 billion, respectively, according to data compiled by LSEG.

    "Our previous guidance had anticipated even faster acceleration of growth for the quarter. That, in addition to lower-than-expected channel inventory at year-end, contributed to our Q4 results," CEO David Ricks said.

    Lilly said it expects 2025 sales between $58 billion and $61 billion. Analysts were expecting revenue of $58.52 billion."

    finance.yahoo.com/news/lilly-forecast...

    Eli Lilly and Company (LLY) 739.32 -58.16 (-7.29%)
    16. Reactie Reactie van: dd20250501
    17. Reactie Reactie van: dd20250807
    18. Reactie
    19. Reactie Reactie van: dd20250817
    20. Reactie Reactie van: dd20251030 Laatste reactie
46 Posts
vorige pagina 1 2 3 volgende pagina
Laatste
Omhoog

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Forumregels | Lees hier het forumreglement

Kwaliteit boven kwantiteit

Lever een duidelijke en constructieve bijdrage aan de discussie. Kwaliteit trekt kwaliteit aan.

Blijf ontopic

beperk je reactie tot het onderwerp van het forumdraadje en haal er geen andere zaken bij.

Respecteer je medemens

Een afwijkende visie op een bedrijf rechtvaardigt geen persoonlijke aanvallen. Reageer op de inhoud van iemands argumenten, niet op de persoon;

Koop deze belegging bij

Laatste artikelen over Eli Lilly & Co

  1. Beursnieuws

    Wall Street wacht voorzichtig herstel

  2. Beursnieuws

    Analyse: Novo’s misstappen vergroten Lilly’s voorsprong in afslankmiddelen

  3. Beursnieuws

    Instant View: CagriSema-tegenslag verschuift focus naar M&A bij Novo, zeggen analisten

  4. Beursnieuws

    Eli Lilly lanceert multi-dosis apparaat voor afslankmedicijn in de VS
Bekijk meer artikelen
naam laatste prijs verschil
Eli Lilly & Co 1.008,390 +18,060 +1,82%